Scholars Central

Research articlePublished 2012

ROLE OF CELECOXIB IN BENIGN BREAST DISEASE: RANDOMISED CONTROL TRIAL

Authors: Soumen Das, Retina Paul

Journal of Pharmaceutical and Scientific Innovation

Volume 1 · Issue 3 · Pages 37–38

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Benign Breast Disease (BBD), commonest cause of morbidity in females due to breast diseases, still offers therapeutic challenge. Several drug therapies (with Evening Primrose Oil, Danazol etc) have been tried, but none made gold standard. Reports on effect of Cox-2 inhibitors are scarce. This randomized control trial aims at determination of effect of Cox- inhibitors (Celecoxib) in BBD in comparison to Evening Primrose Oil (EPO ). Celecoxib showed better reduction in lump size (in 80%) than EPO group (in 50%). Pain reduction was excellent in COX -2 groups as compared to EPO group. Recurrence rate was also lower in Celecoxib group at 10 weeks. Side effects were almost nil in both the groups. Celecoxib is better than EPO in the management of BBD. Short course therapy with COX-2 inhibitors gives good pain relief, greater reduction in lump size, low recurrence with minimum side effects.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Pharmaceutical and Scientific Innovation.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmaceutical and Scientific Innovation
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Soumen Das”
  • BylineArticles whose byline prints “Retina Paul”